

**NOW EXPANDED FDA APPROVAL**


**PD-L1 IHC 22C3 pharmDx identifies KEYTRUDA treatment options for metastatic NSCLC patients**

PD-L1 22C3 IHC pharmDx is the **only** companion diagnostic approved by the FDA as an aid in identifying metastatic NSCLC patients for treatment with KEYTRUDA<sup>®</sup> (pembrolizumab)<sup>1</sup> across all lines of therapy.


Incorporate PD-L1 IHC 22C3 pharmDx into your diagnostic lung panel to provide clinically relevant results linked to patient outcomes.

- High-quality staining results optimized for treatment selection
- Clinically validated scoring guidelines
- Quality assured, all-inclusive kits with control slides
- Comprehensive Interpretation Manual and eLearning

**Add PD-L1 IHC 22C3 pharmDx to your lung panel to inform treatment options for metastatic NSCLC patients**



Tumor Proportion Score  $\geq$  1%. Oncologist to consider KEYTRUDA for previously treated metastatic NSCLC patients\*



Tumor Proportion Score  $\geq$  50%. Oncologist to consider KEYTRUDA for metastatic NSCLC patients\*

\* See the KEYTRUDA product label for expression cutoff values guiding therapy in specific clinical circumstances. KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

## Experience easy integration of PD-L1 testing in your IHC workflow

- Ready-to-Use reagents optimized for Autostainer Link 48
- Cell line controls for enhanced confidence in results
- Results can be available within one working day

## PD-L1 IHC 22C3 pharmDx is a complete diagnostic kit

- 50 tests included
- 15 control slides

### Order Information

Description	Product No.
PD-L1 IHC 22C3 pharmDx	SK006

### Additional Reagents

Description	Product No.
EnVision FLEX Wash Buffer, 20x	K8007
EnVision FLEX Hematoxylin	K8008



### Intended Use

For in vitro diagnostic use.

PD-L1 IHC 22C3 pharmDx is a qualitative immunohistochemical assay using Monoclonal Mouse Anti-PD-L1, Clone 22C3 intended for use in the detection of PD-L1 protein in formalin-fixed, paraffin-embedded (FFPE) non-small cell lung cancer (NSCLC) tissue using EnVision FLEX visualization system on Autostainer Link 48. PD-L1 protein expression is determined by using Tumor Proportion Score (TPS), which is the percentage of viable tumor cells showing partial or complete membrane staining at any intensity. The specimen should be considered to have PD-L1 expression if TPS  $\geq$  1% and high PD-L1 expression if TPS  $\geq$  50%.

PD-L1 IHC 22C3 pharmDx is indicated as an aid in identifying NSCLC patients for treatment with KEYTRUDA<sup>®</sup> (pembrolizumab). See the KEYTRUDA<sup>®</sup> product label for expression cutoff values guiding therapy in specific clinical circumstances<sup>1</sup>.

1. PD-L1 IHC 22C3 pharmDx - Package Insert.

# Trusted Answers. Together.



Agilent Pathology Solutions

[www.dako.com](http://www.dako.com)

Represented in more than 100 countries

**Australia**  
+61 2 9922 0700

**Austria**  
+43 1 408 43 34 0

**Belgium**  
+32 16/93 00 30

**Brazil**  
+55 11 50708300

**Canada**  
+1 800 387 8257

**China**  
+86 21 3612 7091

**Denmark**  
+45 44 85 97 56

**Finland**  
+358 9 348 73 950

**France**  
+33 1 64 53 61 44

**Germany**  
+49 40 69 69 470

**Ireland**  
+353 1 479 0568

**Italy**  
+39 02 58 078 1

**Japan**  
+81 3 5232 9970

**Korea**  
+82 2 2194 9577

**The Netherlands**  
+31 20 42 11 100

**Norway**  
+47 23 14 05 40

**Poland**  
+48 58 661 1879

**Spain**  
+34 93 344 57 77

**Sweden**  
+46 8 556 20 600

**Switzerland**  
+41 41 760 11 66

**United Kingdom**  
+44 (0)1 353 66 99 11

**United States of America**  
+1 805 566 6655